Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

Free Radical Biology and Medicine

Volumn 33, Issue 2, 2002, Pages 266-275

  Barnabé, Norman ^a   Zastre, Jason A ^a   Venkataram, Suresh ^a   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antioxidant; Calcein; Cardiotoxicity; Deferiprone; Doxorubicin; EPR; Free radicals; Iron; Myocyte; Semiquinone

Indexed keywords

DEFERIPRONE; DOXORUBICIN; FERRIC ION; HYDROXYL RADICAL; IRON CALCEIN COMPLEX; IRON COMPLEX; LACTATE DEHYDROGENASE; RAZOXANE; SEMIQUINONE; SUPEROXIDE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE; XANTHINE OXIDASE; ANTINEOPLASTIC AGENT; CALCEIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUORESCEIN DERIVATIVE; FREE RADICAL; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL HYPOXIA; CELL PROTECTION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG MECHANISM; ELECTRON SPIN RESONANCE; ENZYME RELEASE; HEART MUSCLE CELL; HEART PROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION; SPRAGUE DAWLEY RAT;

ANIMAL; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; ELECTRON SPIN RESONANCE SPECTROSCOPY; FLUORESCEINS; FREE RADICALS; INDICATORS AND REAGENTS; IRON; IRON CHELATING AGENTS; LACTATE DEHYDROGENASE; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; SUPPORT, NON-U.S. GOV'T; ANIMALS; L-LACTATE DEHYDROGENASE;

STAPHYLOCOCCUS PHAGE 187;

EID: 0037098878     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(02)00873-0     Document Type: Article

References (44)

1. The biochemical basis of anthracycline toxicity and anti-tumor activity
2. The anthracyclines: Will we ever find a better doxorubicin?
3. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen
4. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex
5. Reappraisal of the association between adriamycin and iron
6. Speciation studies of adriamycin, quelamycin, and their metal ion complexes
7. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system
8. 2 reduction by the iron complexes of adriamycin and daunomycin: The importance of the sidechain hydroxyl group
9. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals
10. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs
11. A comparison of the free radical properties of several anthracycline anti-tumour drugs and some of their analogues
12. Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone)
13. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases
14. Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers
15. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction
16. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
17. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine
18. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)- cyanidanol-3
19. Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte
20. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells
21. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones
22. Chemistry of dioxygen
23. Adenovirus E1A represses cardiac gene transcription and reactivates DNA synthesis in ventricular myocytes, via alternative pocket protein- and p300-binding domains
24. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
25. Chelation and mobilization of cellular iron by different classes of chelators
26. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells
27. 2 injury in adult cardiomyocytes
28. Anthracycline cytoxicity is potentiated by iron and inhibited by deferoxamine: Studies in rat heart cells in culture
29. Reoxygenation-induced cell damage of isolated neonatal rat ventricular myocytes can be reduced by chain-breaking antioxidants
30. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells
31. Spin trapping of superoxide and hydroxyl radical: Practical aspects
32. Spin trapping: ESR parameters of spin adducts
33. Redox cycling of anthracyclines by cardiac mitrochondria. I. Anthracycline radical formation by NADH dehydrogenase
34. Biochemical mechanisms of tumor cell kill by the anthracyclines
35. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
36. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity
37. Membrane transport of anthracyclines
38. Transplasma-membrane redox systems in growth and development
39. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity
40. Chemistry of dexrazoxane and analogues
41. Prevention of doxorubicin-induced damage to heart myocytes by the hydroxypyridinone iron chelator deferiprone (L1, CP20)
42. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells
43. Phase I trials of dexrazoxane and other potential applications for the agent